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Background: In contrast to sessile serrated adenomas and traditional serrated adenomas which are associated with
a significant cancer risk, the role of hyperplastic polyps (HP) in colorectal carcinogenesis as well as the molecular
mechanisms underlying their development remain controversial and still need to be clarified. Several reports
suggest that a subset of HP may represent precursor lesions of some colorectal cancers. However, biomarkers are
needed to identify the subset of HP that may have a malignant potential. The hormone precursor, progastrin (PG)
has been involved in colon carcinogenesis and is known to activate pro-oncogenic pathways such as the ERK or
the STAT3 pathway. We therefore analyzed PG expression and the activation of these signaling factors in HP.
Methods: We retrospectively analyzed PG expression as well as the phosphorylation of ERK and STAT3 by
immunohistochemistry in HP from 48 patients.
Results: Mean percentages of epithelial cells positive for PG or phospho-ERK were respectively, 31% and 33% in HP
and were significantly higher in these lesions compared to normal colon (3%, p = 0.0021 and 7%, p = 0.0008,
respectively). We found a significant correlation between PG and phospho-ERK expression in HP with ERK activation
significantly stronger in lesions with high progastrin expression (p = 0.015). In contrast, STAT3 was not significantly
activated in HP compared to normal colon and we did not observe a significant correlation with PG expression.
Conclusions: HP overexpressing PG that have the highest activation of the ERK pathway might reflect less latent
lesions that might have a malignant potential.
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Among colorectal polyps, the serrated adenomas repre-
sent a heterogeneous group of lesions including, sessile
serrated adenomas (SSA) and traditional serrated aden-
omas (TSA). They are associated with a significant cancer
risk and represent neoplastic precursor lesion of serrated
adenocarcinomas [1,2]. Both SSA and TSA have a high
frequency of DNA methylation. However, SSA have been
linked to adenocarcinomas with microsatellite instability
(MSI) with a positive immunostaining for Cytokeratin 7
(CK7) and mostly localized in the proximal colon. In con-
trast TSA are essentially microsatellite stable or show
low level of MSI and lead to serrated adenocarcinomas* Correspondence: cathy.seva@inserm.fr
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reproduction in any medium, provided the orin the distal colon with a positive immunostaining for
CK7 and CK20. In addition, SSA are frequently BRAF-
mutated whereas TSA show a high frequency of K-ras
mutations [3-5].
The hyperplastic polyps (HP) are the most frequently
occurring lesions in the colon with prevalence in west-
ern populations of 10% to 35% [6]. HP are usually consid-
ered as innocuous lesions with no malignant potential.
However, large HP (size > 10 mm) and the presence of
multiple HP (number > 5) in hyperplastic polyposis syn-
drome have been clearly associated with colorectal aden-
omas or adenocarcinoma [7-10]. However, some authors
have proposed that a subset of HP may be associated to
an increased risk to develop adenomas. Huang et al. [11]
found that patients with HP on initial colonoscopic exam-
ination have an increased incidence of colorectal aden-
omas on follow-up colonoscopy. In addition, we recentlyThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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without history of colorectal pathology, presenting initial
true HP (<10 mm) with no SSA or TSA features, subse-
quently developed adenomas after resection of these
HP [12]. Interestingly HP from patients who developed
adenomas overexpressed the prohormone progastrin (PG)
which is recognized as a growth factor, playing an import-
ant role in colon carcinogenesis [12].
PG is the precursor of the amidated gastrin. This hor-
mone is mainly produced by antral G cells of the stom-
ach and is known as a potent stimulant of gastric acid
secretion [13]. In colorectal cancers, gastrin gene expres-
sion is up-regulated [14]. However, in these tumors, gas-
trin is incompletely maturated and gastrin precursors,
particularly PG, are mainly secreted. High concentra-
tions of PG are found in colon tumors and in blood of
patients with colorectal cancer. PG is also expressed in
adenomatous polyps [15-17]. In contrast, this hormone
precursor is absent from the healthy intestinal epithe-
lium. The proliferative effects of PG on normal and can-
cerous colorectal cells in vitro and in vivo have been
clearly established [18-25]. In addition transgenic mice
overexpressing progastrin present an increased prolifera-
tive index in colonic mucosa. They also have an increased
risk of developing preneoplastic lesions in colonic epithe-
lium [22]. These effects are mediated through the acti-
vation of signaling pathways such as the extracellular
signal-regulated kinase (ERK) and the signal transducer
and activator of transcription 3 (STAT3) pathways [20].
These pathways that transduce extracellular signals to the
nucleus and regulate gene transcription are known to be
activated in many human cancers, including colorectal
cancer [20,26-30]. They have been shown to regulate cell
functions involved in carcinogenesis, such as cell prolifera-
tion, survival or migration. In the present study, to better
characterize at the molecular level the subset of HP that
may be associated with a risk to develop colonic neo-
plasm, we assessed the activation of the ERK and STAT3
pathways in HP and we analyzed the correlation with PG
expression.
Methods
Patients and data collection
We examined 48 cases of HP (from 48 different patients)
diagnosed in the pathology department of Rangueil
Hospital (Toulouse, France) in 2008. We excluded pa-
tients with a history of familial adenomatous polyposis or
hyperplastic polyposis and HP which display criteria of
sessile serrated adenomas according to Torlakovic [9,31].
All polyps measured less than 1 cm with an average diam-
eter of 3 mm. For comparison, we also selected 12 normal
colonic tissue specimens from resected non-complicated
diverticular disease and 15 adenomas (10 low, and 5 high
grade dysplasia adenomas). Clinical data (age, gender, site,size, number of HP at diagnosis, history of colorectal ad-
enoma, or adenocarcinoma and the presence of synchron-
ous adenoma or adenocarcinoma were collected for all 48
patients (Table 1). Approval of an institutional research
ethics committee (Medical University of Toulouse) was
obtained in accordance with the precepts of the Helsinki
Declaration.
Immunohistochemistry
For immunohistochemistry on the formaldehyde-fixed,
paraffin embedded tissues, antigen retrieval was per-
formed on dewaxed sections by water-bath heating slides
in 10 mM Tris-EDTA buffer (pH9) (Cliniscience, Nan-
terre, France). After peroxidase and serum blocking, pri-
mary antibodies was applied overnight. We then, used
the Dako Envision + System-HRP according to manufac-
turer protocol (Cliniscience). Specific primary polyclonal
antibody against PG used for immunohistochemistry
(dilution: 1:1000) was previously characterized [12,32].
Primary monoclonal antibodies against tyrosine705-
phospho-STAT3 (pY-STAT3) and threonin202/tyrosin204-
phospho-ERK-1/2 (pERK1/2) (dilution 1:400) were provided
by Cell Signaling Technology, Inc. (Danvers, MA, USA).
PG antibodies were provided by the University of Mel-
bourne, Department of Surgery (Victoria, Australia). Co-
lonic tissue sections known to be positive for PG, p-ERK
and p-STAT3 were used as positive controls. For negative
controls the primary antibody was omitted. In addition,
the anti-PG antibody was incubated with the immunizing
peptide that abolished the staining reaction. Analysis of
the whole polyp section was performed. Staining for PG
(cytoplasmic), p-ERK (cytoplasmic) and p-STAT3 (nuclear)
were measured by percentage of stained epithelial cells in
the whole polyp. All specimens were examined in a double
blinded fashion by two pathologists trained to identify the
pathological features of colonic cancer. The coefficient of
concordance correlation, c-rho [33] was calculated in order
to determine inter-rater agreement for immunohisto-
chemistry staining. Because the inter-rater agreement was
excellent (c-rho =0.99 for progastrin and pY-STAT3; and
c-rho = 0.98 for p-ERK staining), percentages were re-
ported as the average results between the two readers. As
defined in our previous work [12], progastrin staining was
also recorded as no/low, moderate or high expression.
The “normality” threshold of progastrin expression (low
expression) was determined using the 95th percentile of
percentage of stained cells in normal colonic tissue (<10%).
Moderate expression of progastrin was defined as staining
in 10% to 50% of epithelial cells and high expression as
staining in more than 50% of epithelial cells.
Using the 95th percentile of percentage of p-ERK stained
epithelial cells in normal mucosa, we defined p-ERK over-
expression as staining in more than 15% of epithelial cells.
Moderate expression (defined as staining in 15% to 50% of
Table 1 Clinical and histological features of hyperplastic polyps
Variables Total of HP Progastrin staining in HP epithelial cells
N = 48 No/Low expression Moderate expression High expression p-value
N = 21 N = 12 N = 15
Age, mean (SD) 65 y.o.(12) 61 y.o.(14) 68 y.o (10) 68 y.o (8) 0.2613
Median [min-max] 66 y.o. [30–89] 65 y.o. [30–80] 70 y.o. [51–89] 66 y.o. [53–79]
Sex, % (95% CI) 0.019
Female 44% [29%-59%] 33% [15%-57%] 25% [5%-57%] 73% [45%-92%]
Male 56% [41%-71%] 67% [43%-85%] 75% [43%-95%] 27% [8%-55%]
History of adenoma or adenocarcinoma, % (95% CI) 29% [17%-44%] 33% [15%-57%] 42% [15%-72%] 13% [2%-40%] 0.280a
Synchronous Adenoma or
adenocarcinoma, % (95% CI)
48% [33%-63%] 48% [26%-70%] 33% [10%-65%] 60% [32%-84%] 0.387
Localisation, % (95% CI) 0.154a
Proximal colon 27% [15%-42%] 19% [5%-42%] 17% [2%-48%] 47% [21%-73%]
Distal colon 73% [58%-85%] 81% [58%-95%] 83% [52%-98%] 53% [27%-79%]
HP histologic features 0.784a
Goblet-cell rich HP 83% [70%-93%] 81% [58%-95%] 92% [62%-100%] 80% [52%-96%]
Microvesicular HP 17% [7%-30%] 19% [5%-42%] 8% [0%-38%] 20% [4%-48%]
Progastrin expression was analyzed as a 3 classes variable: no/low expression, moderate expression and high expression as detailed in “Methods”. Chi 2 tests
(for categorical variables) and Kruskal-Wallis test (for continuous variables) were performed to compare clinical and immune-histological features between
progastrin expression groups. 95% CI: Binomial exact 95- confidence interval was calculated for each percentage, if no other mention. SD: standard deviation a:
Fischer exact test.
Figure 1 Distribution of percentage of progastrin stained
epithelial cells in HP. No/low expression of progastrin was
determined using the 95th percentile of percentage of stained cells
in normal colonic mucosa (<10%). Among HP overexpressing the
prohormone (>10%), moderate expression (10%-50%) and high
expression (>50) were distinguished accordingly to the bimodal
distribution of progastrin expression.
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(staining in more than 50% of epithelial cells).
Using the 95th percentile of percentage of pY-STAT3
stained epithelial cells in normal mucosa, we defined pY-
STAT3 overexpression as staining in more than 5% of
epithelial cells. High expression was defined as staining
in more than 50% of epithelial cells.
Statistical analysis
Univariate analysis was conducted to compare clinical
and immunohistochemistry findings between the differ-
ent study groups using the Chi2 test or Fisher exact test
(when required) for categorical variables and the nonpara-
metric rank tests (Wilcoxon-Mann–Whitney or Kruskal_-
Wallis) or Cuzick nonparametric test for trend across
ordered groups for quantitative variables.
Spearman nonparametric correlation test was used to
assess the correlations between the expression of progas-
trin and p-ERK or pY-STAT3.
All tests were two-sided and statistical significance was
set at a p value of 0.05.
***p < 0.001; **0.001 < p < 0.01; *0.01 < p < 0.05. Analyses
were performed using the statistical software, STATA
v11 [34].
Results
Clinical and histological characteristics
Clinical and histological features of patients and their
polyps as well as PG staining in HP epithelial cells are
shown in Table 1. To take into account the heterogeneityof PG staining in HP observed in Figure 1, PG expression
was analyzed in Table 1 as a 3 classes variable as detailed
in “Methods”. In our sample, no/low expression of progas-
trin was observed in 44% of the HP (95% CI: 29%-59%),
moderate expression in 25% (14%-40%) and strong ex-
pression in 31% (19%-46%). Although an increased preva-
lence of HP with high PG expression can be observed in
women, PG expression was not significantly correlated to
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oma, synchronous adenoma or carcinoma, localization and
HP histological features.
Expression of progastrin in normal mucosa and colonic
neoplasms
Representative pictures of PG staining, obtained with the
anti-PG antibody in normal colon, HP, low grade and high
grade adenomas are shown in Figures 2 and 3. The percent-
ages of PG-positive cells in these different sample tissues
are reported in Figure 4A. Mean percentage of PG positive
cells observed in the 48 HP was significantly higher than inFigure 2 Expression of Progastrin p-ERK1/2 and pY-STAT3 in hyperpl
B) high progastrin staining. (C, D) p-ERK1/2 staining in HP: C) no/weak stai
E) no/weak staining F) high pY-STAT3 staining.normal colon (respectively 31% and 3% p = 0.0021). In low
and high grade tubular adenomas, percentages of PG posi-
tive cells were also higher compared to normal colon
(respectively, 87%, p = 0.0001 and 85%, p = 0.0014). No sig-
nificant difference was observed between low and high
grade adenomas. HP showed an intermediate expression of
PG between normal mucosa and colonic adenomas.
The ERK pathway in normal colonic mucosa, HP and
adenomas and its relationship with progastrin expression
Representative pictures of p-ERK1/2 staining in normal
colon, HP, low grade and high grade adenomas are shownastic polyps. (A, B) Progastrin staining in HP: A) no/weak staining
ning D) high p-ERK1/2 staining. (E, F) pY-STAT3 staining in HP:
Figure 3 Expression of Progastrin p-ERK1/2 and pY-STAT3 in normal colonic mucosa and adenomas. (A-C) Progastrin staining: A) Negative
staining in normal colon B) high progastrin staining in low grade and C) high grade adenomas. (D-F) p-ERK1/2 staining: D) Negative staining E) high
p-ERK1/2 staining in low grade and F) high grade adenomas. (G-I) pY-STAT3 staining: G) Negative staining in normal colon H) high pY-STAT3 staining
in low grade and I) high grade adenomas.
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cells in these different sample tissues are reported in
Figure 4B. Mean percentage of p-ERK positive epithe-
lial cells in normal colonic tissues reached 7%. In HP,
the activation of ERK was significantly higher, with 33% of
stained epithelial cells (p = 0.0008). In low grade and high
grade adenomas, mean percentages of stained cells were
similar (51%) and significantly higher than in normal mu-
cosa (respectively, p = 0.0002 and p = 0.0105).
Interestingly, in HP, ERK activation was significantly
higher in lesions with strong PG expression (53% of stained
cells) as compared to no/low or moderate PG expression
(respectively 29% and 22%, p = 0.015) (Table 2). As de-
scribed in “methods” we also defined 3 groups for p-ERKexpression. 65% of HP presented an overexpression of p-
ERK, including 37% of moderate expression and 28% of
high expression. Analysis of the increase in percentage
across the different expression groups showed that the
expression of p-ERK and PG was significantly correlated
(p = 0.008) (Table 2).
The STAT3 pathway in normal colonic mucosa HP and
adenomas and its relationship with progastrin expression
Representative pictures of pY-STAT3 staining in normal
colon, HP, low grade and high grade adenomas are shown
in Figures 2 and 3.
The percentages of pY-STAT3-positive cells in these
different sample tissues are reported in Figure 4C. Mean
Figure 4 Progastrin, p-ERK1/2, and pY-STAT3 expression in
colonic tissues. Percentage of (A) progastrin (B) p-ERK1/2
(C) pY-STAT3 positive cells for normal colon, Hyperplastic polyps
(HP), low grade dysplasia tubular adenomas and high grade dysplasia
tubular adenomas. Quantifications are presented as means ± S.E.M.
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mucosa was only 1%. In HP the percentage of stained
cells was 10% but was not significantly higher than in
normal colonic mucosa. In low grade and high grade
adenomas, mean percentages of stained cells were re-
spectively 38% and 31% and significantly higher than in
normal mucosa (respectively, p = 0.0014 and p = 0.0041).
As observed for PG and P-ERK no significant differ-
ence in PY-STAT3 staining was observed between low
and high grade adenomas.
3 groups for pY-STAT3 expression were defined as de-
scribed in “Methods”. 23% of HP presented an overex-
pression of pY-STAT3, including 14% with moderate
expression and 9% with high expression (Table 2). In HP,
mean percentage of pY-STAT3 staining was not associ-
ated to the different classes of PG staining (p = 0.297)
and no correlation between these two factors was ob-
served (p = 0.3116).
Discussion
In the present study, we demonstrated a significant in-
crease in the activation of the pro-oncogenic pathway,
ERK1/2, in HP as compared to normal tissue. More
interestingly, we showed a significant correlation be-
tween ERK pathway activation in HP and the expression
of PG that is recognized as a growth factor for colonic
epithelial cells. ERK activation was significantly higher in
lesions with strong PG expression. Activation of this sig-
naling pathway by PG has been previously reported in
normal colonic epithelial cells from a transgenic mouse
model overexpressing PG and has been linked to an in-
creased risk of developing preneoplastic lesions in the co-
lonic epithelium [20]. Therefore HP overexpressing PG
that have a high activation of the ERK pathway might re-
flect less latent lesions.
The PG gene has been previously shown to be a target
of two pro-oncogenic pathways frequently activated in
colorectal cancer: APC/β-catenin and K-ras [35-37].
APC deletions or β-catenin mutations have not been re-
ported in HP and we recently published that this path-
way is not activated in HP with PG overexpression [12].
Therefore, it is unlikely that this pathway is involved in
the expression of PG in these lesions. In contrast, KRAS
mutations have been observed in thirty-seven percent of
HP [5] and might lead to the increase in PG expression
and ERK activation observed in the present study. How-
ever we cannot exclude an additional mechanism leading
to PG expression in HP since in our study, nearly to
Table 2 Expression of progastrin, p-ERK1/2 and pY-STAT3 in hyperplastic polyps
Variables Total Progastrin staining in HP epithelial cells
N = 48 No/Low expression Moderate expression High expression p-value
N = 21 N = 12 N = 15
Percentage of p-ERK1/2 stained cells, N mean (SD) N = 43 33% (30) N = 18 27% (29) N = 12 23% (22) N = 13 53% (29) 0.015a
Expression of p-ERK1/2 0.008b
No/low expression 35% [21%-51%] 50% [26%-74%] 42% [15%-72%] 8% [0%-36%]
Moderate expression 37% [23%-53%] 33% [13%-59%] 42% [15%-72%] 38% [14%-68%]
High expression 28% [15%-44%] 17% [4%-41%] 16% [2%-48%] 54% [25%-81%]
Percentage of pY-STAT3 stained cells, N mean (SD) N = 35 10% (23) N = 15 11% (29) N = 7 3% (7) N = 13 12% (23) 0.297
Expression of pY-STAT3 0.3116
No/low expression 77% [60%-90%] 80% [52%-96%] 86% [42%-100%] 69% [39%-91%]
Moderate expression 14% [5%-30%] 7% [0%-32%] 14% [0%-58%] 23% [5%-54%]
High expression 9% [2%-23%] 13% [2%-40%] 0% [0%-41%] 8% [0%-36%]
SD: standard deviation.
(a)Cuzick test for trend across ordered groups.
(b)Spearman nonparametric correlation test was used for comparison of ordered qualitative variable.
Expressions of PG, .P-ERK and PY-STAT3 were analyzed as a 3 classes variable: no/low expression, moderate expression and high expression as detailed
in “Methods”.
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or p-ERK. In a recent publication, Bongers et al. [38]
have reported the activation of the EGFR pathway in
seventy percent of HP from a small cohort of 27 sam-
ples. Interestingly, EGFR ligands have been shown to be
potent regulators of the progastrin gene and an EGF re-
sponse element has been identified on the progastrin
promoter [39,40]. Therefore the EGFR pathway activated
in HP might also contribute to PG overexpression and
ERK activation independently of K-ras.
Progastrin is clearly recognized as an autocrine growth
factor for colorectal cancer cells and blocking PG ex-
pression has been shown to inhibit cellular growth
in vitro and in vivo on tumor xenografts [23,41,42]. It
is probable that an autocrine mechanism occurs in HP
producing PG and leading to ERK activation. However a
recent publication from Duckworth et al. [43] suggests
that an indirect mechanism might be also proposed. These
authors have shown that PG is capable to activate colonic
fibroblasts leading to growth factors secretion that in turn
stimulate colonic epithelial cells. These results therefore
suggest that PG produced by HP might also activate the
ERK pathway in colonic epithelial cells via a dialogue with
the fibroblasts present in the stroma.
The identity of the receptor mediating the PG effects
on colonic epithelial cells or fibroblasts remains an im-
portant point of debate. Several publications have shown
that the receptor specific for the mature form of gastrin,
the CCK-2 receptor, is not involved in the PG effect on
fibroblasts or colon cancer cells [18,43,44]. In contrast
the data from Jin et al. [45] suggest a role of this recep-
tor in the proliferative effects of PG in vivo, although the
nature of the interaction between PG and the CCK2receptor in this study remains to be identified. Other
studies have shown a role of ferric ions, Annexin A2 or
glycosaminoglycans in the binding of PG to cell surface
[20,46,47]. However, the cell surface protein that directly
binds PG remained to be identified.
In contrast to what we observed for the ERK pathway,
STAT3 activation was not significantly different between
HP and normal colon. In addition we did not observe a
significant correlation with PG expression. We previ-
ously demonstrated an association between STAT3 acti-
vation and PG in vivo, in transgenic mice overexpressing
the prohormone [20]. STAT3 activation by PG might re-
quired high level of progastrin expression, as found in
adenomas or adenocarcinomas.
Previously we demonstrated that PG expression in HP
may predict occurrence of metachronous adenomas
[12]. Including additional biomarkers might improve the
specificity of such a test. P-ERK might be an interesting
factor since this pro-oncogenic factor is overexpressed
in a subset of PG positive HP.
Conclusion
HP overexpressing PG that have the highest activation
of the ERK pathway might reflect less latent lesions that
might have a malignant potential.
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